NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹163 Cr | ₹118 Cr | ₹87 Cr | ₹58 Cr | ₹66 Cr |
What is the latest Total Current Liabilities ratio of NGL FINECHEM ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹163 Cr |
| Mar2025 | ₹118 Cr |
| Mar2024 | ₹87 Cr |
| Mar2023 | ₹58 Cr |
| Mar2022 | ₹66 Cr |
How is Total Current Liabilities of NGL FINECHEM Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹163 Cr | 37.30 | |
| Mar2025 | ₹118 Cr | 36.77 | |
| Mar2024 | ₹87 Cr | 48.54 | |
| Mar2023 | ₹58 Cr | -11.21 | |
| Mar2022 | ₹66 Cr | - | |
Compare Total Current Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,769.8 Cr | -8.4% | 3.4% | 97.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹449,228.0 Cr | -0.8% | 7.3% | 7.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹293,874.0 Cr | -3.3% | 21.8% | 68.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,413.0 Cr | -1.7% | 1.9% | 22.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹116,604.0 Cr | 0.7% | 12.4% | 12.4% | Stock Analytics | |
| CIPLA | ₹114,720.0 Cr | 0.7% | 6.7% | -9.4% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -8.4% |
3.4% |
97.3% |
| SENSEX | 0.2% |
9.8% |
-2.9% |
You may also like the below Video Courses